Results 261 to 270 of about 21,053 (285)

Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: A randomized clinical trial of biomarker targets

International Journal of Stroke
Background: This study aimed compare efficacy of edoxaban and enoxaparin upon biomarkers of hypercoagulability in patients with cancer-related embolic stroke of undetermined source (ESUS).
Jong-Won Chung, Jaechun Hwang, Hyung Jun Kim, Woo-Keun Seo, Myung-Ju Ahn, J. Saver, O. Bang   +6 more
semanticscholar   +1 more source

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation

Annals of Internal Medicine, 2022
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau, C. O. Torre, Kenneth K C Man, H. M. Stewart, S. Seager, Mui Van Zandt, Christian Reich, Jing Li, Jack Brewster, G. Lip, A. Hingorani, Li Wei, I. Wong   +12 more
semanticscholar   +1 more source

Edoxaban

Reactions Weekly, 2023
  +7 more sources

Effectiveness and Safety of Edoxaban Compared With Apixaban in Elderly Patients With Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study

Stroke
BACKGROUND: The very elderly (≥80 years) are at high risk of nonvalvular atrial fibrillation and thromboembolism. Given its recent approval, the comparative effectiveness and safety of edoxaban in this population, relative to the commonly used apixaban ...
Richard Chiv, Sarah Beradid, S. Suissa, Christel Renoux   +3 more
semanticscholar   +1 more source

Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation

Circulation. Cardiovascular Quality and Outcomes
BACKGROUND: Cardiovascular trials often use a composite end point and a time-to-first event model. We sought to compare edoxaban versus warfarin using the win ratio, which offers data complementary to time-to-first event analysis, emphasizing the most ...
Brian A. Bergmark, Jeong-Gun Park, Rose A. Hamershock, Giorgio E. M. Melloni, R. De Caterina, E. Antman, C. Ruff, H. Rutman, Michele F. Mercuri, H. Lanz, E. Braunwald, Robert P. Giugliano   +11 more
semanticscholar   +1 more source

Edoxaban

Reactions Weekly, 2019
  +6 more sources

Firstly electrochemical investigetions and determination of anticoagulant drug edoxaban at single-use pencil graphite electrode: an eco-friendly and cost effective voltammetric method

DARU Journal of Pharmaceutical Sciences, 2023
Abdulkadir Kiliç, M. Aslan, G. Önal, A. Levent   +3 more
semanticscholar   +1 more source

A disposable edoxaban sensor chip using carbon paste electrode grafted with molecularly imprinted polymer

Journal of Artificial Organs, 2023
Y. Yoshimi, Shohei Kani, Aaryashree
semanticscholar   +1 more source

Edoxaban-induced acute interstitial nephritis

CEN Case Reports
Shiko Gen, Ririko Higashi, Natsuki Nagae, Ryuta Kigure, Yuta Kamikubo, Kanako Nobe, Naofumi Ikeda   +6 more
semanticscholar   +1 more source

A promising green fluorimetric approach for analysis of edoxaban in real human plasma using green carbon dots decorated with terbium ions

Chemické zvesti
Y. F. Hassan, Eman Alzahrani, Roshdy E. Saraya, Mohamed A. Abdel-Lateef, Ehab A. M. El-Shoura, Hany A. Batakoushy, Adel Ehab Ibrahim, Abd‐ElAziem Farouk, Mohamed A. A. Abdel-Aal, Baher I. Salman   +9 more
semanticscholar   +1 more source